Avalo Therapeutics Reports First Results Since LOTUS Trial Success Changed Everything—Or Did It

Avalo Therapeutics (AVTX) is scheduled to report first-quarter 2026 earnings on May 11, 2026, with the stock trading at $21.57 ahead of the release. The central question for investors is whether the company can sustain the dramatic improvement seen in its most recent quarter—when it delivered a stunning 76% earnings beat—or if that result was an anomaly amid a broader pattern of significant misses. With the stock up 164% over the past year and analysts overwhelmingly bullish, this report will test whether AVTX's clinical progress can translate into sustained financial performance.

Part 1: Earnings Preview

Avalo Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for cardiometabolic, fibrotic, and inflammatory diseases through its proprietary long-acting prodrug platform. The company's lead asset, AVTX-009 (abdakibart), is currently in a Phase 2 LOTUS trial for hidradenitis suppurativa, with topline data expected in the second quarter of 2026.

For the first quarter of 2026, analysts expect AVTX to report a loss of $1.00 per share based on a consensus of 4 estimates ranging from $0.85 to $1.10. This represents a 20% improvement from the $1.25 loss reported in the same quarter last year. The most recent quarter (Q4 2025) saw the company report a loss of $0.37 per share, dramatically beating the $1.54 consensus estimate by 76%—a stark contrast to the pattern of significant misses in the three quarters prior.

Three key themes define this earnings story heading into the release:

Clinical Trial Momentum and Data Readout Timing: The LOTUS trial officially completed patient dosing in March 2026, and topline data is expected in Q2 2026. Investors will scrutinize management commentary for any updates on the data timeline and early signals about trial progress. The trial enrolled approximately 250 patients, and its success is critical given AVTX's heavy dependence on this single lead asset.

Cash Burn and Capital Runway: With $98.3 million in cash as of year-end 2025 and persistent operating losses exceeding $70 million annually, the company's ability to fund operations through key clinical milestones remains a central concern. The recent restructuring of a $15 million milestone payment related to the AlmataBio acquisition—announced April 26, 2026—highlights ongoing capital management challenges. Analysts will focus on updated cash guidance and whether additional financing will be needed before data readout.

Revenue Collapse and Path to Commercialization: Annual revenue plummeted 87% to just $59,000 in fiscal 2025, reflecting the company's transition away from legacy assets to focus entirely on AVTX-009. With no meaningful revenue stream, the company's valuation hinges entirely on the clinical success of its lead program and the potential for future commercialization or partnership opportunities.

Ahead of the release, analysts have grown increasingly optimistic. HC Wainwright raised its Q1 2026 EPS estimate from $1.76 to $1.10 on March 25, 2026, citing improved cost management. The firm maintains a Buy rating with a $40 price target. Guggenheim initiated coverage in February 2026 with a Buy rating and $50 target, while BTIG Research reiterated its Buy rating and $40 target following the Q4 results. The analyst community now includes 13 Strong Buy ratings and just 1 Hold, with price targets ranging from $24 to $62 and a mean of $43.09—implying 100% upside from current levels.

Part 2: Historical Earnings Performance

Avalo Therapeutics has demonstrated an inconsistent earnings track record over the past four quarters, with three significant misses followed by a dramatic beat in the most recent period. In Q1 2025, the company reported a loss of $1.25 per share versus the $1.07 estimate, missing by 17%. The misses intensified through the middle of 2025: Q2 saw a $1.92 loss against a $1.43 estimate (34% miss), and Q3 delivered a $2.19 loss versus the $1.67 consensus (31% miss).

The pattern reversed sharply in Q4 2025, when AVTX reported a loss of just $0.37 per share against expectations of $1.54—a stunning 76% beat that represented the company's first positive earnings surprise in the available history. This dramatic improvement appears to reflect both better cost control and the winding down of certain legacy expenses as the company focused resources on its lead AVTX-009 program.

The volatility in earnings performance—swinging from 17-34% misses to a 76% beat—suggests significant variability in the company's cost structure and the timing of R&D expenses. For the upcoming Q1 2026 report, the $1.00 consensus estimate represents a 20% improvement from the $1.25 loss in the year-ago quarter, but investors should be cautious about extrapolating the Q4 beat into a sustained trend given the erratic historical pattern.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Avalo Therapeutics typically reports earnings before market open, meaning Day 0 represents the first trading session where investors react to results, and Day +1 captures follow-through momentum.

Historical price action around AVTX earnings shows moderate volatility with an average absolute Day 0 move of 2.86% and Day +1 move of 3.29%. The most recent earnings release on March 23, 2026, saw relatively muted reaction despite the massive earnings beat—the stock gained just 0.60% on Day 0 and declined 0.37% on Day +1, with intraday ranges of 8.01% and 12.07% respectively.

The largest post-earnings moves occurred in mid-2024 and late 2025: the August 2024 report triggered a 7.30% Day 0 decline, while the November 2025 release saw a 6.26% Day 0 drop followed by further weakness. Conversely, the August 2025 report produced a 6.95% Day +1 gain. The Day 0 trading ranges have averaged 8.52%, while Day +1 ranges have averaged 10.07%, indicating significant intraday volatility regardless of the directional close.

Investors should expect meaningful price movement around this release, with historical patterns suggesting the Day +1 session often produces larger moves than the initial reaction as the market digests management commentary and analyst responses.

Part 2.2: Options Market Expected Move

The options market is pricing a 9.86% expected move for the May 15, 2026 expiration (7 days out), with an implied range of $19.19 to $23.39. This expected move is notably higher than the historical average Day 0 move of 2.86% and Day +1 move of 3.29%, suggesting options traders are anticipating above-average volatility for this particular release—likely reflecting heightened uncertainty around clinical trial commentary and cash runway guidance ahead of the critical Q2 data readout.

Part 3: What Analysts Are Saying

Analyst sentiment on Avalo Therapeutics is overwhelmingly bullish, with the stock carrying an average recommendation of 4.86 out of 5.0—firmly in Strong Buy territory. The current consensus includes 13 Strong Buy ratings, 0 Moderate Buys, 1 Hold, and 0 Sell ratings across 14 analysts covering the stock. The mean price target of $43.09 implies 100% upside from the current price of $21.57, with estimates ranging from a low of $24.00 to a high of $62.00.

Analyst sentiment has improved over the past month, with Strong Buy ratings increasing from 12 to 13 while the Hold rating remained steady at 1. The average recommendation ticked up slightly from 4.85 to 4.86, reflecting growing confidence in the company's clinical prospects as the LOTUS trial data readout approaches.

The bullish consensus is anchored by several recent upgrades and initiations. Guggenheim's February 2026 initiation at Buy with a $50 target cited the compelling risk-reward profile ahead of Phase 2 data, while HC Wainwright's March 2026 estimate revision reflected improved visibility on cost management. BTIG Research has maintained its $40 target, and Wolfe Research initiated coverage in April 2026 with an Outperform rating and $48 target. Even the single Hold rating from Weiss Ratings (which assigned a "sell (d-)" technical rating) is offset by Mizuho's upgrade to Strong Buy in December 2025.

The wide range in price targets—from $24 to $62—reflects the binary nature of the investment thesis: success in the LOTUS trial could drive substantial upside, while failure would likely result in significant downside. The clustering of targets in the $40-50 range suggests most analysts are modeling a probability-weighted scenario that assumes reasonable odds of clinical success.

Part 4: Technical Picture

The Barchart Technical Opinion for AVTX has shifted dramatically in recent weeks, moving from a 72% Sell signal one week ago to a 40% Buy signal currently, and improving from a 24% Sell signal one month ago. This rapid reversal reflects the stock's strong momentum heading into earnings, with shares surging from the mid-teens to above $21 in a matter of days.

Timeframe Analysis:

• Short-term (Hold): Neutral reading suggests the recent rally may be consolidating after the sharp move higher
• Medium-term (Hold): Neutral signal indicates the intermediate trend is balanced between bullish momentum and potential resistance
• Long-term (100% Buy): Strong buy signal confirms the dominant uptrend remains intact over the longer timeframe

Trend Characteristics: The trend is characterized by Average strength but is Weakening, suggesting the recent rally may be losing steam as the stock approaches earnings and investors take profits ahead of the binary event.

The stock is trading above all major moving averages, including the 5-day ($19.26), 10-day ($16.39), 20-day ($15.27), 50-day ($15.54), 100-day ($15.91), and 200-day ($14.57). This alignment confirms strong technical momentum, with the stock up 164% over the past 12 months and breaking out to new highs in recent sessions.

Key technical levels to watch include the $19.19 support level (the lower bound of the options expected move) and the $23.39 resistance level (the upper bound). The stock's position well above all moving averages provides a technical cushion heading into earnings, but the "Weakening" trend direction and elevated short interest of 29% of basic shares suggest vulnerability to profit-taking if results or guidance disappoint. The overall technical setup is supportive but stretched, with the stock having already priced in considerable optimism ahead of the release—making execution and forward guidance critical to sustaining the rally.